An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality by Aliot, Etienne et al.
.....................................................................................................................................................................................
.....................................................................................................................................................................................
CLINICAL RESEARCH
Atrial Fibrillation – Clinical Issues
An international survey of physician and patient
understanding, perception, and attitudes to atrial
ﬁbrillation and its contribution to cardiovascular
disease morbidity and mortality
EtienneAliot1*,G u ¨nterBreithardt2, JosepBrugada3, JohnCamm4, GregoryY.H.Lip5,
PanosE.Vardas6,andMarkusWagner7fortheAtrialFibrillationAWarenessAndRisk
Education (AF AWARE) group [comprising the Atrial Fibrillation Association (AFA),
the European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE),
and the World Heart Federation (WHF)]
1Brabois Hospital, University Hospital of Nancy, Nancy, France;
2Department of Cardiology and Angiology, University Hospital of Mu ¨nster, Mu ¨nster, Germany;
3University of
Barcelona, Barcelona, Spain;
4St George’s Hospital Medical School, London, UK;
5University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK;
6Heraklion University Hospital, Crete, Greece; and
7Prevention Department, German Stroke Foundation, Guetersloh, Germany
Received 8 December 2009; accepted after revision 22 March 2010
Aims Atrial ﬁbrillation (AF) is not always perceived as a serious health threat, but is the most common sustained arrhyth-
mia, with a major impact on morbidity, mortality, and patient quality of life (QoL). A survey was undertaken to
examine the level of understanding, perception, and attitudes of the cardiovascular risks associated with AF.
Methods and
results
The AF AWARE group (an international coalition of organizations with an interest in AF) conducted an international
quantitative survey in 11 countries in 2009, to investigate patients’ (n ¼ 825) and cardiologists’ (n ¼ 810) perceptions
of AF, preferences for communicating information on AF and burden of AF. Both patients and physicians considered
AF life-threatening (55 and 43%, respectively). Physicians were more concerned about the risk of stroke and hospi-
talizations than patients, whereas patients were most concerned about death risk. One in four patients felt unable to
explain AF and .33% were worried or fearful about their disease. Many physicians (51%) wanted more patient infor-
mation with .60% viewing available information as poor/difﬁcult to ﬁnd. Hospital specialists and GPs were identiﬁed
as key information sources for patients. Most patients (83%) reported symptoms, yet 75% claimed to be satisﬁed with
AF therapies. Atrial ﬁbrillation patients, often with associated diseases, made an average of nine visits per year to their
doctors, who consider AF difﬁcult and time consuming to manage. Patients and physicians rated the QoL impact of
AF as moderate to high.
Conclusions A comprehensive international patient and professional information and support programme on AF is needed to
improve management and consequently health outcomes.
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Atrial ﬁbrillation (AF) is the most common sustained heart rhythm
disorder and a condition associated with high mortality and mor-
bidity.
1–5 The condition has been described as epidemic in pro-
portion, with AF prevalence predicted to triple by 2050.
6,7 The
lifetime risks for development of AF are one in four for people
over the age of 40 years.
8
Whether silent or symptomatic, AF is typically a progressive
condition, worsening over time.
9 It is associated with an increased
mortality risk, as well as an increased risk of developing congestive
heart failure and serious thrombo-embolic events.
1,5,10–12 Indeed,
the mortality rate of patients with AF is approximately double that
of patients with normal sinus rhythm. Atrial ﬁbrillation has been
shown to increase the risk of ischaemic stroke up to ﬁve-fold,
1,11
and such strokes tend to be more severe than strokes linked
with other causes.
13,14 There is also a close relationship between
AF and heart failure, which is associated with poor prognosis, in
which AF aggravates heart failure, which in turn promotes AF.
2
The presence of AF in patients with other co-morbid cardiovascu-
lar (CV) diseases worsens prognosis and contributes to the risk of
sudden death.
15,16 Atrial ﬁbrillation is also associated with substan-
tial healthcare costs, and adding to the health–economic burden
posed by AF is evidence that the condition has a negative impact
on patients’ daily living activities and quality of life (QoL).
17–20
Nonetheless, there are concerns that AF is not perceived as a
serious health threat. This condition can be overlooked by the
medical community, who fail to accept AF as a readily modiﬁable
risk factor for CV morbidity and mortality.
21–23 Patients also
have limited awareness and poor perception of the broader risks
associated with a diagnosis of AF.
24,25
To better understand physicians’ and patients’ knowledge, per-
ceptions, and attitudes to AF and its contribution to CV morbidity
and mortality, a survey incorporating physician and patient ques-
tionnaires was conducted in association with the AF AWARE
group (Atrial Fibrillation AWareness And Risk Education)—a colla-
borative activity between the World Heart Federation (WHF), the
Stroke Alliance for Europe (SAFE), the Atrial Fibrillation Associ-
ation (AFA), and the European Heart Rhythm Association
(EHRA). This article reports the ﬁndings of this survey, with the
aim of identifying potential gaps between the realities of AF and
the perception of AF as a public health concern that may be
addressed through improved educational intervention.
Methods
Members of the AF AWARE group provided input into the develop-
ment of and the interpretation of results, from an international quan-
titative survey. The survey comprised two questionnaires; one of the
questionnaires focused on obtaining responses from patients with
AF, and the other addressed physicians active in the management of
AF. Through parallel and complementary questionnaires, the survey
sought information on respondents’ (physician and patient) level of
understanding of AF and AF risk, perception of AF relative to other
medical conditions, practices and preferences for communicating infor-
mation on AF, and the burden and QoL impact of AF. The aim of the
survey was to assess the level of understanding of AF and identify
differences, gaps, misconceptions, and shortcomings in both physicians’
and patients’ perception of AF as a serious CV disease. The survey was
undertaken between February and April 2009, and the results were
reviewed and interpreted by members of the AF AWARE group.
Random sampling and recruitment
The physician survey aimed to recruit a total of 810 physicians (cardi-
ologists/electrophysiologists) under the age of 60 years. A cut-off age
of 60 years was used to ensure that all physicians surveyed were below
retirement age and still in clinical practice. The physician group com-
prised representatives from 11 countries (USA, Canada, Mexico,
Brazil, UK, France, Germany, Spain, Italy, China, and Australia). These
countries were chosen to provide a representative global spread of
viewpoints. Recruitment aimed at about 75 physicians per country
(except Australia, which aimed to recruit about 60 since the total
national population and therefore the potential pool of cardiology pro-
fessionals is smaller than that for other larger countries).
The majority of physicians who took part in the survey were
sampled by random selection from existing physician panel databases
(databases of physicians who have agreed to take part in market
research) (68%) and accessed by the Taylor Nelson Sofres (TNS)
Healthcare group. In order to achieve the required level of physician
recruitment per country, there was a need for TNS to source a
further 32% of physicians via public and private databases listing cardi-
ologists. The panel database:public/private database share for each par-
ticipating country therefore differed: Mexico 40:60%; Canada 50:50%;
Brazil 80:20%; UK, USA, France, Germany, Spain, and Italy 100:0%;
China and Australia 0:100%.
The AF patient sample was selected through a number of routes
including patient panels (databases of patients who have agreed to
be contacted for potential participation in market research studies),
patient-support organizations, and via physician recommendations.
Physicians could not select (only suggest) patients to take part in the
survey, and the patient and physician surveys were performed entirely
independently so that there was no physician inﬂuence on patient
recruitment. The majority of patients were recruited from patient
panels, and only 2.8% were from patient-support groups. In common
with the physician survey, the patient group recruited comprised
patients (825) drawn from 11 countries (75 per country; countries
as per physician survey). Consent to participate was required from
all patients, and some patients declined the invitation or withheld
consent. Reasons given for not participating included difﬁculty in
hearing or not feeling comfortable discussing their condition.
For both the physician and patient questionnaires, screening ques-
tions were employed to gather demographic data, to exclude patients
without a conﬁrmed diagnosis of AF, and to ensure that physicians
recruited were directly involved in the management of patients with
AF (a minimum of 20 patients with AF managed per month).
Data acquisition
With the exception of Brazil, where 60% of physicians completed the
survey by phone and 40% used the on-line questionnaire, 100% of the
physicians from the other countries completed the survey on-line. For
the patient survey, 43% of patients completed the survey via the Inter-
net as an on-line questionnaire, 40% by structured telephone inter-
view, and 17% through face-to-face interviews. No individual patient
data were reported. No direct incentive was offered to physicians or
patients to take part in the survey.
Scope of the survey
The scope of the survey and its main questions were reviewed by the
AF AWARE group, who subsequently appraised the survey results.
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dent ﬁve-point rating scale) sought information on physicians’ evalu-
ation of the risks associated with AF and AF treatments relative to
other CV diseases/treatments. Views on language used to describe
AF, types of communication, and level and adequacy of information
currently provided to patients with AF were collated, as well as phys-
icians’ perceptions of the level of patient familiarity with AF (risks, man-
agement, treatments). The frequency and nature of consultations
provided to patients with AF and their satisfaction with AF manage-
ment, as well as the physicians’ perception regarding patient QoL
and the health–economic impact of AF, were also part of the scope
of the survey.
The patient survey of 26 questions (many employing rating scales)
soughtinformationonpatients’estimateandratingoftheriskofAFrela-
tive to other diseases. Levelof understanding/familiarity with features of
AF, as well as how patients deﬁne their preferred sources of, and satis-
factionwith, informationonAFandAFtreatments wasalsodetermined.
Patient views and descriptions of how AF impacts on daily living were
sought. To aid patients in comparing AF with other medical conditions,
the patient survey also included simple descriptions of comparator dis-
eases. Brief descriptions of AF were also provided for patients who
might have been uncertain of the key clinical features of AF.
Statistics
The survey was carried out to gauge opinion and perceptions of AF
and its treatment. Many of the questions to physicians solicited their
perception of patient viewpoints and understanding. In order to
apply a quantitative element to the mixture of viewpoints and percep-
tions revealed by the survey and to allow comparisons to be made
between physician and patient answers to related questions, Student
t-tests were used, employed with 95% thresholds of signiﬁcance, and
individual P-values are provided, where appropriate.
Results
A total of 810 physicians and 825 patients from 11 countries took
part in the survey. Key features of the disease proﬁle of patients
with AF, including AF diagnostic history, are provided in Figure 1.
The survey screening questions on demographics identiﬁed that
83% of patients experienced symptoms of AF, with 27% reporting
that they had one or more episodes of AF per week. Among the
patients surveyed, 20% reported that they had AF as an on-going,
long-term episode that did not terminate on medical intervention.
More than half of patients described their AF symptoms as moder-
ate (33%) or severe (11%) in answer to screening questions.
Perceptions of atrial ﬁbrillation risks and
atrial ﬁbrillation management
Physicians and patients had differing perceptions of the threat to
health and mortality posed by AF and its relative risk in relation
to other medical conditions or risk factors. Atrial ﬁbrillation was
considered life-threatening by 43% of physicians and by 55% of
patients. Physicians ranked AF as posing a lower threat to life
than diabetes, stroke, and heart attack. Patients rated AF as less
life-threatening than heart attack, stroke, and hypertension but
more life-threatening than diabetes.
Physician and patient beliefs regarding the risk associated with
AF and clinical events differed. Physicians were more concerned
Figure 1 Key features of the history of atrial ﬁbrillation (AF) disease and diagnosis reported by patients.
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whereas patients were more concerned about the risks of death
or sudden cardiac death or of a heart attack.
Atrial ﬁbrillation management: understanding
and satisfaction
Of the patients surveyed, 88% reported that they were receiving
some form of treatment for their AF. Of that group, 75% were
receiving anticoagulants, 61% rhythm control therapy, and 46%
rate control therapy.
There was a tendency for physicians to underestimate their
patients’ understanding of the beneﬁts of AF treatments and to
overestimate patients’ knowledge about treatment complications
(Figure 2). Overall, there was a relatively high level of patient
knowledge of the beneﬁts of medication and their side effects,
and of possible complications of AF. However, patients felt less
familiar with more speciﬁc issues like the role for electrical cardi-
oversion, ablation of AF, and the development of new medications.
Patient satisfaction with treatment tended to be underestimated
by physicians (Figure 3). Physicians’ own satisfaction with AF treat-
ments was low relative to other CV medications. In terms of AF
treatments and their efﬁcacy and safety proﬁles, physicians
ranked AF treatments lower (at position 6) than therapies used
in the management of high cholesterol, hypertension, heart
attack, asthma, and diabetes (ranked 1–5, respectively), but
above treatments for depression and stroke.
Atrial ﬁbrillation caseload
The survey found that AF patients visit a physician between 8 and
11 times a year. Recurrent episodes of AF that last more than 7
days were associated with the greatest need for physician visits
(more than 10 visits per year). A total of 26% of patients said
they visited the cardiologist every 6 months, 22% once every
3 months, and 17% every month.
Physicians rated AF as the third most demanding condition (after
heart attack and heart failure) and the second most difﬁcult con-
dition (after heart attack) to manage in practice, out of a list of con-
ditions that also included stroke, angina, diabetes, hypertension,
high cholesterol, depression, asthma, and cessation of smoking.
Only heart failure ranked consistently higher than AF in terms of
management difﬁculty and demands on time. More than one in
four physicians felt that AF was either too complicated to
explain to patients or that they did not have enough time to
fully explain AF in their consultations with patients.
Information and communication
Physician opinion was that the level and quality of information
about AF provided to patients compared poorly with levels of
information provided on other common clinical conditions, par-
ticularly other CV diseases (Figure 4).
When asked to score their patients’ ability to explain AF, the
average rating score was 2.6 (on a ﬁve-point scale). Thus, 46% of
physicians rated patient ability to explain AF as poor, whereas
24% of patients rated their own ability to explain AF as poor
and at least one in four patients with AF felt unable to explain
their condition to another person.
Physicians considered that 51% of their patients with AF have an
important need for more and improved information. Only 35% of
physicians agreed that information provided by physicians to patients
on AF was easy to understand, and only 20% felt there was enough
educational information on AF for patients. A total of 60% of phys-
icians believed that patients had trouble sourcing information on AF.
Patient views on the level of information provided on AF were
varied, with 57% of patients agreeing that information provided by
the physician was easy to understand, whereas 23% of patients
reported that they did not know where to look, or whom to
contact, to get information on AF. Physicians believed that 60%
of patients are satisﬁed with the level of information provided.
Figure 2 Patient knowledge about atrial ﬁbrillation (AF) and its management. Physicians’ estimates and perceptions of their patients’ famili-
arity with aspects of treatment compared with patients’ own familiarity ratings of aspects of atrial ﬁbrillation treatments. Percentage of respon-
dents rating aspects of atrial ﬁbrillation treatment (perceived patient view, actual patient view) as not familiar (scores 1–2), neutral (3), and
familiar (4–5), mean score rating, mean score rating difference between physicians and patients.
Survey of physician and patient understanding, perception, and attitudes to AF 629Both physicians and patients considered that specialist physicians
and GPs werethe core group ofhealthcare professionalsto provide
on-going patient support and information on AF (Figure 5). In
addition, 46% of patients said they searched for more information
on AF, or requestedinformation on AF, in an attempt to understand
their disease and its management more fully.
Perceptions of patient concerns
and quality of life
Over one-third of patients were worried or fearful about their AF
(Table 1).
Both physicians and patients rated AF as having an adverse
impact on patient QoL. Consequences of an AF diagnosis such
as hospitalization, recurrent symptoms, treatment monitoring,
limitations on physical function, altered general health, limitations
on social activities, and patients’ altered mental health all had
‘some’ to ‘high’ impact on their patients’ daily function.
Discussion
The survey ﬁndings suggest that patients’ level of understanding of
AF is often insufﬁcient to allow appreciation of the risks conferred
by AF and highlights that patients often have a poor understanding
of AF management and treatment.
Around 25% of patients felt unable to explain their condition.
These ﬁndings are in keeping with the literature on patient
Figure 3 Patient satisfaction with atrial ﬁbrillation (AF) treatments. Physicians’ estimates and perceptions of their patients’ satisfaction with
atrial ﬁbrillation treatments compared with patients’ own satisfaction ratings for atrial ﬁbrillation treatments. Percentage of respondents rating
aspects of atrial ﬁbrillation treatment (perceived patient view, actual patient view) as not satisﬁed (scores 1–2), neutral (3), and satisﬁed (4–5).
Figure 4 Physician satisfaction with level of information and educational materials provided to patients with atrial ﬁbrillation compared with
information provided on other clinical conditions. Percentage of physicians rating information as poor (scores 1–2) or neutral (score 3).
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in a study of 93 patients with AF, nearly half of all patients could
not name their condition and did not understand the role of antic-
oagulant treatment for AF. However, after those patients were
given literature and verbal explanations on AF and its treatment,
rates of understanding improved.
26 The current literature high-
lights that patients with risk factors (including AF) are often
unable to identify their health condition as a risk factor for
stroke and have low-risk perceptions about their health status.
23,24
In this survey, physicians assumed that their patients would have
quite low levels of understanding of the nature of AF and its man-
agement. Physicians’ own perceptions of the risks associated with
AF were closely aligned with the clinical facts and data regarding
AF risks.
1,11,12
In this survey, over 50% of patients only had their AF recognized
during routine check-ups or while consulting for another con-
dition. Better identiﬁcation and appropriate treatment of AF at
an earlier time point in the course of this often progressive
disease could help reduce both the clinical burden and health–
economic impact associated with AF.
1,11,12,17,18
Physicians and patients differed in their views about, and satisfac-
tion with, AF management and treatment. Although more than half
of physicians were either neutral about or dissatisﬁed with treat-
ments, patients reported that they were highly satisﬁed with treat-
ments offered for AF. High levels of satisfaction with treatment
were voiced despite the fact that over 80% of the patient
surveys reported on-going AF symptoms.
More than one-third of patients reported that they were
worried or afraid about their AF and stated that they need more
reassurance and counselling on their condition. This observation
seems at odds with patient reports of satisfaction with their
current AF management and may indicate that patients feel
resigned to their situation rather than able to affect it through
their own actions or via consultations with their physician. It is
known that one-third of AF patients experience persistent
depression,
20 and anxiety is common among newly diagnosed
patients.
27
Despite guidelines on AF management,
5 there is some evidence
in the literature that physicians may be reluctant to employ treat-
ments for AF that could reduce AF risks because of concerns
about safety. For example, a study of physicians’ attitudes
towards the use of antithrombotic drugs suggested uncertainties
among GPs and cardiologists about the most appropriate use of
these drugs,
23 and similar lack of conﬁdence in, and awareness
of, treatments has been reported in other studies and
reviews.
22,28 Experience in other CV disease areas suggests that
Figure 5 Patients’ preferred sources for receiving information on atrial ﬁbrillation, and physicians’ perceptions of their patients’ preferred
information sources.
................................................................................
Table 1 A comparison of physicians’ perception of
patient-worry about atrial ﬁbrillation and actual
patient-reported feelings about atrial ﬁbrillation
Reported or
perceived feelings
about AF
AF patients
reporting a
feeling (%)
Physician
perceptions of
patient feelings (%)
Afraid 5 13
Worried 29 22
Neither reassured
nor worried
20 23
Quite reassured 33 20
Very reassured 13 22
Values are percentage of respondents who selected each answer option.
Survey of physician and patient understanding, perception, and attitudes to AF 631better adherence to guidelines and better education around the
risk and beneﬁts of treatments are needed to improve patient
management.
29
The apparent gaps between patient and physician understand-
ing of AF reported in the survey could be interpreted as highlight-
ing a need to support patients through better information
provision and education. A recent study which followed a
group of patients during the ﬁrst 12 months after AF diagnosis
noted that anxiety was the main, and a common, affective
response.
27 That same study concluded that addressing AF
patients’ anxiety should constitute a key element of patient man-
agement and should happen early in the process of establishing a
good patient–physician relationship.
27 These ﬁndings are
reinforced by the current survey which illustrated that patients
see healthcare professionals, particularly GPs, as their most
important source of information. However, this observation is
confounded by the fact that 60% of physicians surveyed believe
that the availability of quality information is inadequate for
patient counselling and that patients have trouble sourcing infor-
mation. Furthermore, physicians overestimated patients’ use of
the Internet as an information source.
In keeping with the literature on AF, this survey found that a
diagnosis of AF had considerable impact on QoL and daily
living.
17–20,27,30–32 In older people (aged ≥65 years) with AF,
almost all studies of health-related QoL identify lower QoL out-
comes in AF patients, and also identify that better control of
heart rate can improve health-related QoL in these patients.
32
The socio-economic burden posed by AF was also highlighted
by the survey ﬁndings. Physicians ranked AF as a condition
placing high demand on their time, and it was found that AF man-
agement required frequent consultations. There is evidence that
early assessment and appropriate educational intervention to
help improve patient’s knowledge may reduce hospitalizations
and potentially improve long-term health outcomes.
26,33
There are limitations to patient and physician surveys inherent
within the need to recruit from databases of respondents willing
and able to give time to answering a set of pre-deﬁned questions.
Sampling from such databases may not provide a representative
real practice cohort of either physicians treating AF or patients
with AF. In the patient sample reported here, for example, 20%
of patients stated they had continuous AF and more than half
had moderate-to-severe AF, suggesting that this was a group of
patients not representative of the population in general but repre-
sentative of AF patients who are typically managed by a cardiolo-
gist. The survey used different methods of data collection—on-line
and verbal interviews—which may have affected the responses
obtained. However, the use of standard questions and rating
scales should have ensured consistency of answers regardless of
interview method. The survey sought opinion and perceptions of
AF and its treatment, and many physician questions solicited phys-
ician opinions on patients’ beliefs. As such, the survey responses,
even those involving a rating scale, remain viewpoints and percep-
tions in the main and do not allow strict statistical comparisons of
data points. However, the strength of this study is its contempor-
ary and parallel assessment of patient and physician views, which
offer a unique opportunity to examine gaps and differences in
understanding between these groups.
In conclusion, this survey of patients with AF and physicians
managing AF provides unique, international insights into levels of
understanding by patients and their physicians of the risks posed
by AF. A comprehensive international patient and professional
information and support programme on AF is urgently needed
and further clinical studies to conﬁrm the long-term beneﬁts of
an intervention-based approach are warranted.
Acknowledgements
The survey was conducted by the TNS Healthcare group.
The AF AWARE Group would like to thank Dr Winnie McFad-
zean for her editorial support (consolidating author amends, for-
matting, styling) in the preparation of this manuscript.
Conﬂict of interest: E.A. has received consulting fees from
sanoﬁ-aventis, Cardiome, Meda Pharma, St Jude, Biotronic, Med-
tronic, Sorin Ela Medical. G.B. has been a member of advisory
boards for sanoﬁ-aventis, Boehringer-Ingelheim, Bayer, Boston-
Scientiﬁc, and Medtronic. He has received honoraria for lectures
at various meetings from such companies. He is a member of
steering committees of trials sponsored by Bayer, Johnson &
Johnson, Cordis, Meda Pharma Germany, and sanoﬁ-aventis. J.C.
has received consulting fees from and has been a member of the
speakers’ bureau for sanoﬁ-aventis, Cardiome, Astellas, Merck,
Bayer, Boehringer Ingleheim, ARYx, and Bristol Myers Squibb.
G.Y.H.L. has been a member of advisory boards for sanoﬁ-aventis,
Boehringer-Ingelheim, Bayer, Astellas, and Astra Zeneca. He has
received honoraria for lectures at various meetings from such
companies.
Funding
This work was supported by sanoﬁ-aventis, who provided funding for
the survey, editorial support, and an unrestricted educational grant to
the AF AWARE group. Funding to pay the Open Access charges for
this paper was provided by sanoﬁ-aventis.
References
1. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact
of atrial ﬁbrillation on the risk of death: the Framingham Heart Study. Circulation
1998;98:946–52.
2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal
relations of atrial ﬁbrillation and congestive heart failure and their joint inﬂuence
on mortality: the Framingham Heart Study. Circulation 2003;107:2920–5.
3. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agaostino RB et al. A risk
score for predicting stroke or death in individuals with new-onset atrial ﬁbrillation
in the community: the Framingham Heart Study. JAMA 2003;290:1049–56.
4. Lip GY, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ. Oral anticoagulation
in atrial ﬁbrillation: a pan-European patient survey. Eur J Intern Med 2007;18:
202–8.
5. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/
AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation:
a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines and the European Society of Cardiology Com-
mittee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines
for the Management of Patients with Atrial Fibrillation): developed in collabor-
ation with the European Heart Rhythm Association and the Heart Rhythm
Society. Circulation 2006;114:e257–e354.
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of
diagnosed atrial ﬁbrillation in adults: national implications for rhythm management
and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation
(ATRIA) Study. JAMA 2001;285:2370–5.
7. Savelieva I, Camm J. Update on atrial ﬁbrillation: part I. Clin Cardiol 2008;31:55–62.
E. Aliot et al. 6328. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime
risk for development of atrial ﬁbrillation: the Framingham Heart Study. Circulation
2004;110:1042–6.
9. Kato T, Yamashita T, Sagara K, Iinuma H, Fu LT. Progressive nature of paroxysmal
atrial ﬁbrillation. Observations from a 14-year follow-up study. Circ J 2004;68:
568–72.
10. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-
term risks associated with atrial ﬁbrillation: 20-year follow-up of the Renfrew/
Paisley study. Am J Med 2002;113:359–64.
11. Wolf PA, Abbott RD, Kannel WB. Atrial ﬁbrillation as an independent risk factor
for stroke: the Framingham Study. Stroke 1991;22:983–8.
12. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk
proﬁle from the Framingham Study. Stroke 1991;22:312–8.
13. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ et al. Stroke
severity in atrial ﬁbrillation. The Framingham Study. Stroke 1996;27:1760–4.
14. Dulli DA, Stanko H, Levine RL. Atrial ﬁbrillation is associated with severe acute
ischemic stroke. Neuroepidemiology 2003;22:118–23.
15. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP et al. Inci-
dence and prognostic signiﬁcance of atrial ﬁbrillation in acute myocardial infarc-
tion: the GISSI-3 data. Heart 2001;86:527–32.
16. Pedersen OD, Abildstrom SZ, Ottesen MM, Rask-Madsen C, Bagger H, Kober L
et al. Increased risk of sudden and non-sudden cardiovascular death in patients
with atrial ﬁbrillation/ﬂutter following acute myocardial infarction. Eur Heart J
2006;27:290–5.
17. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial
ﬁbrillation in the United States, 1985 through 1999: implications for primary pre-
vention. Circulation 2003;108:711–6.
18. Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D, Maggioni AP et al. Costs
of atrial ﬁbrillation in ﬁve European countries: results from the Euro Heart Survey
on atrial ﬁbrillation. Europace 2008;10:403–11.
19. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial ﬁbrilla-
tion: a systematic review. Am J Med 2006;119:448. e1–e19.
20. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in
patients with atrial ﬁbrillation. Chest 2007;132:1259–64.
21. Murphy NF, Simpson CR, Jhund PS, Stewart S, Kirkpatrick M, Chalmers J et al. A
national survey of the prevalence, incidence, primary care burden and treatment
of atrial ﬁbrillation in Scotland. Heart 2007;93:606–12.
22. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, De Reuck J et al. Stroke pre-
vention and atrial ﬁbrillation: reasons leading to an inappropriate management.
Main results of the SAFE II study. Br J Clin Pharmacol 2004;57:798–806.
23. Peterson GM, Boom K, Jackson SL, Vial JH. Doctors’ beliefs on the use of antith-
rombotic therapy in atrial ﬁbrillation: identifying barriers to stroke prevention.
Intern Med J 2002;32:15–23.
24. Dearborn JL, McCullough LD. Perception of risk and knowledge of risk factors in
women at high risk for stroke. Stroke 2009;40:1181–6.
25. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient
perceptions of atrial ﬁbrillation and anticoagulation therapy: the West Birming-
ham Atrial Fibrillation Project. Stroke 2002;33:238–42.
26. Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and percep-
tions of atrial ﬁbrillation and anticoagulant therapy: effects of an educational inter-
vention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol
2006;110:354–8.
27. Lane DA, Langman CM, Lip GYH, Nouwen A. Illness perceptions, affective
response, and health-related quality of life in patients with atrial ﬁbrillation.
J Psychosom Res 2009;66:203–10.
28. Camm AJ. Safety considerations in the pharmacological management of atrial
ﬁbrillation. Int J Cardiol 2008;127:299–306.
29. Bramlage P, Thoenes M, Kirch W, Lenfant C. Clinical practice and recent rec-
ommendations in hypertension management—reporting a gap in a global
survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin
2007;23:783–91.
30. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM et al. The impair-
ment of health-related quality of life in patients with intermittent atrial ﬁbrillation:
implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;
36:1303–9.
31. Singh SN, Tang XC, Singh BN, Dorian P, Reda DJ, Harns CL et al. Quality of life
and exercise performance in patients in sinus rhythm versus persistent atrial ﬁbril-
lation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol
2006;48:721–30.
32. Lane DA, Lip GY. Quality of life in older people with atrial ﬁbrillation. J Interv Card
Electrophysiol 2009;25:37–42.
33. Gillis AM, Burland L, Arnburg B, Kmet C, Pollak PT, Kavanagh K et al. Treating the
right patient at the right time: an innovative approach to the management of atrial
ﬁbrillation. Can J Cardiol 2008;24:195–8.
Survey of physician and patient understanding, perception, and attitudes to AF 633